MK0869, aprepitant / Duration of Treatment: 3 days

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Breast NeoplasmsNauseaVomiting

Phase 3

Study of MK0869 for the Prevention of Chemotherapy-Induced Nausea and Vomiting (0869-071)(COMPLETED)

CompletedNCT00092196

Merck Sharp & Dohme LLCBreast Neoplasms, Nausea, Vomiting

Start: 2002-12-01End: 2004-12-01Updated: 2017-05-05

Phase 4

Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)

CompletedNCT00090207

Merck Sharp & Dohme LLCNausea, Vomiting

Start: 2004-01-13End: 2004-09-30Updated: 2017-04-24

An Investigational Drug for the Prevention of Chemotherapy-Induced Nausea and Vomiting (MK-0869-071)

CompletedNCT00092183

Merck Sharp & Dohme LLCBreast Neoplasms, Nausea, Vomiting

Start: 2002-10-10End: 2004-02-11Updated: 2017-05-05